Valuing Improvement in Value-Based Purchasing

Department of Public Health, Weill Cornell Medical College, 402 East 67th Street, New York, NY 10065, USA.
Circulation Cardiovascular Quality and Outcomes (Impact Factor: 5.04). 02/2012; 5(2):163-70. DOI: 10.1161/CIRCOUTCOMES.111.962811
Source: PubMed

ABSTRACT Medicare will soon implement hospital value-based purchasing (VBP) using a scoring system that rewards both achievement (absolute performance) and improvement (performance increase over time). However, improvement is defined so as to give less credit to initial low performers than initial high performers. Because initial low performers are disproportionately hospitals in socioeconomically disadvantaged areas, these institutions stand to lose under Medicare's VBP proposal.
We developed an alternative improvement scale and applied it to hospital performance throughout the United States. By using 2005 to 2008 Medicare process measures for acute myocardial infarction (AMI) and heart failure (HF), we calculated hospital scores using Medicare's proposal and our alternative. Hospital performance scores were compared across 5 locational dimensions of socioeconomic disadvantage: poverty, unemployment, physician shortage, and high school and college graduation rates. Medicare's proposed scoring system yielded higher overall scores for the most locationally advantaged hospitals for 4 of 5 dimensions in AMI and 2 of 5 dimensions for HF. By using our alternative, differences in overall scores between hospitals in the most and least advantaged areas were attenuated, with locationally advantaged hospitals having higher overall scores for 3 of 5 dimensions for AMI and 1 of 5 dimensions for HF.
Using an alternative VBP formula that reflects the principle of "equal credit for equal improvement" resulted in a more equitable distribution of overall payment scores, which could allow hospitals in both socioeconomically advantaged and disadvantaged areas to succeed under VBP.

  • [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: -Heart failure (HF) readmission rates are primarily derived from Medicare enrollees. Given increasing public scrutiny of HF readmissions, understanding the rate and predictors in populations covered by other payers is also important, particularly among patients with systolic dysfunction, for whom most HF-specific therapies are targeted. METHODS AND RESULTS: -MarketScan(®) Commercial and Medicaid Administrative Claims Databases were used to identify all first hospitalizations with an ICD-9 discharge diagnosis code for HF (primary position) and systolic HF (any position) between 1/1/2005 and 6/30/2008. Among 4,584 unique systolic HF index admissions (mean age 55 years), 30-day crude readmission rates were higher for Medicaid than commercially insured patients: all-cause 17.4% v. 11.8%; HF-related 6.7% v. 4.0%, respectively. In unadjusted analysis, higher comorbidity and prior healthcare utilization predicted readmission; age, gender, and plan type did not. After adjustment for case mix, the odds of all-cause and HF-related readmission were 32% and 68% higher, respectively, among Medicaid than commercially insured patients (p <0.02 for both). No significant differences in readmission rates were seen for managed care versus fee-for-service or capitated versus non-capitated plan types. CONCLUSIONS: -Compared to commonly cited Medicare HF readmission rates of 20-25%, Medicaid patients with systolic HF had lower 30-day readmission rates, and commercially insured patients had even lower rates. Even after adjustment for case mix, Medicaid patients were more likely to be readmitted than commercially insured patients, suggesting that more attention should be focused on readmissions among socio-economically disadvantaged populations.
    Circulation Heart Failure 10/2012; 5(6). DOI:10.1161/CIRCHEARTFAILURE.112.967356 · 5.95 Impact Factor
  • Circulation Cardiovascular Quality and Outcomes 03/2012; 5(2):148-9. DOI:10.1161/CIRCOUTCOMES.112.965178 · 5.04 Impact Factor
  • Nursing management 10/2013; 44(10):13-5. DOI:10.1097/01.NUMA.0000434466.90084.30